On 15 April, TYRX announced that the first ever implantation of its new AIGISRx R Fully Resorbable Antibacterial Envelope took place at the Quebec Heart and Lung Institute in Quebec City, Canada by François Philippon.
TYRX announced on 31 January 2013 that it received a license from Health Canada to market its AIGISRx R Fully Resorbable technology.
The AIGISRx R Antibacterial Envelope is specifically designed to stabilise electronic implantable devices, such as pacemakers and defibrillators, while also releasing antimicrobial agents to help provide protection from microbial colonisation of the device during surgical implantation.
“Surgical site infections are on the rise and have profound consequences to the patient with regard to having to spend extra time in the hospital, having to undergo additional surgical procedures, and having significant increases in morbidity and mortality. They are also very expensive to treat,” said Philippon, cardiac electrophysiologist at the Quebec Heart and Lung Institute. “I found implantation of the fully resorbable envelope to be very straightforward and believe that the combination of stabilisation and locally delivered antibiotics provided by the product will be of great potential benefit to our patients.”
“We are very excited to have the world’s first AIGISRx R Antibacterial Envelope implanted at the Quebec Heart and Lung Institute,” commented Robert White, TYRX president and CEO. “The AIGISRx R includes all of the advantages of the original AIGISRx, such as stability and infection reduction, but now with the added benefit of full resorption in approximately nine weeks.”
